Genomic response to interferon-α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics

Hepatology

Volumn 43, Issue 5, 2006, Pages 961-972

  Lanford, Robert E ^a   Guerra, Bernadette ^a   Lee, Helen ^a   Chavez, Deborah ^a   Brasky, Kathleen M ^a   Bigger, Catherine B ^a,b  

^a SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PEGINTERFERON ALPHA2A; PROTEIN CXCL 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INOCULATION; LIVER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANIMALS; ANTIVIRAL AGENTS; DOWN-REGULATION; GENOME, VIRAL; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; PAN TROGLODYTES; TIME FACTORS;

EID: 33646573998     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21167     Document Type: Article

References (49)

1. Thomas D, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-398.
2. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2005;20:17-35.
3. Feld J, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-972.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
6. El Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:(5 Suppl 1)S27-S34.
7. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of imerferon-α therapy. Science 1998;282:103-107.
8. Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. HEPATOLOGY 2005;42:749-754.
9. Lam NP. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. HEPATOLOGY 1997;26:226-231.
10. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001;75:7059-7066.
11. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78:13779-13792.
12. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002;99:15669-15674.
13. Chen LM, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-1444.
14. Helbig KJ, Lau DTY, Semendric L, Harley HAJ, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. HEPATOLOGY 2005;42:702-710.
15. Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. HEPATOLOGY 2003;38:1458-1467.
16. Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. HEPATOLOGY 2003;37:610-621.
17. Jaekel E, Cornberg M, Mayer J, Koerbel JN, Wedemeyer H, Schueler A, et al. Early treatment of acute hepatitis C infection with interferon-alpha-2B monotherapy prevents develoment of chronic HCV infection. N Engl J Med 2001;345:1-6.
18. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290:1972-1974.
19. Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003;77:1092-1104.
20. Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
21. Demers GW, Sugarman BJ, Beltran JC, Westreich LN, Iqbal Ahmed CM, Lau JY, et al. Interferon-a2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles. Toxicol Appl Pharmacol 2002;180:36-42.
22. Lanford RE, Guerra B, Demers GW, Chang S, Sugarman BJ, Maneval DC, et al. Gene therapy for chronic hepatitis C based on adenoviral-mediated transfer of interferon-2b gene study based on the chimpanzee model. HEPATOLOGY 2000;32(Suppl):445A.
23. Lanford RE, Chavez D, Notvall L, Brasky KM. Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia. Virology 2003;311:72-80.
24. Lanford RE, Estlack LE. A cultivation method for highly differentiated primary chimpanzee hepatocytes permissive for hepatitis C virus replication. Methods Mol Med 1998;19:501-516.
25. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI, et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 2003;17:455-460.
26. D'Cunha J, Knight EJ, Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A 1996;93:211-215.
27. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004;5:699-701.
28. Foy E, Li K, Sumpter R, Loo YM, Johnson CL, Wang CF, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005;102:2986-2991.
29. Foy E, Li K, Wang CF, Sumpter R, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145-1148.
30. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005;19:727-740.
31. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3. Cell 2005;122:669-682.
32. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-1- and Mda5-mediated type I interferon induction. Nat Immunol 2005;6:981-988.
33. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005;437:1167-1172.
34. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005;175:2851-2858.
35. Rothenfusser S, Goutagny N, DiPerna G, Gong M, Monks BG, Schoenemeyer A, et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol 2005;175:5260-5268.
36. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon ACM, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005;102:2992-2997.
37. Helbig KJ, Ruszkiewicz A, Semendirc K, Harley HAJ, McColl SR, Beard MR. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. HEPATOLOGY 2004;39:1220-1229.
38. Hokeness KL, Kuziel WA, Biron CA, Salazar-Mather TP. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J Immunol 2005;174:1549-1556.
39. Lanford RE, Guerra B, Chavez D, Bigger CB, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol 2004;78:1575-1581.
40. Geiss G, Jin G, Guo J, Bumgarner R, Katze MG, Sen G. A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J Biol Chem 2001;276:30178-30182.
41. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998;95:15623-15628.
42. Hayashi J, Stoyanova R, Seeger C. The transcriptorne of HCV replicon expressing cell lines in the presence of alpha interferon. Virology 2005;335:264-275.
43. Larner AC, Chaudhuri A, Darnell JE Jr. Transcriptional induction by interferon: new protein(s) determine the extent and length of the induction. J Biol Chem 1986;261:453-459.
44. Friedman RL, Manly SP, McMahon A, Kerr IM, Stark GR. Transcriptional and postranscriptional regulation of interferon-induced gene expression in human cells. Cell 1984;38:745-755.
45. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989;58:729-739.
46. Yamagata T, Nishida J, Tanaka S, Sakai R, Mitani K, Yoshida M, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon regulated genes. Mol Cell Biol 1996;16:1283-1294.
47. Nelson N, Marks MS, Driggers PH, Ozato K. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol Cell Biol 1993;13:588-599.
48. Ungureanu D, Silvennoinen O. SLIM Trims STATs: Ubiquitin E3 ligases provide insights for specificity in the regulation of cytokine signaling. Sci STKE 2005;2005:e49.
49. Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD, et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 2006;7:33-39.